Publication: In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos)
1
Issued Date
2007-02-01
Resource Type
ISSN
00029637
Other identifier(s)
2-s2.0-34047092852
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Tropical Medicine and Hygiene. Vol.76, No.2 (2007), 245-250
Suggested Citation
Mayfong Mayxay, Marion Barends, Alan Brockman, Anchalee Jaidee, Shalini Nair, Dan Sudimack, Tiengkham Pongvongsa, Samlane Phompida, Rattanaxay Phetsouvanh, Tim Anderson, Nicholas J. White, Paul N. Newton In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). American Journal of Tropical Medicine and Hygiene. Vol.76, No.2 (2007), 245-250. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/24592
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos)
Abstract
Recent drug trials in Laos have shown high levels of Plasmodium falciparum resistance to chloroquine, but there are no published data on in vitro antimalarial drug susceptibility. We used the double-site enzyme-linked pLDH immunodetection (DELI) assay to estimate the in vitro antimalarial drug susceptibility of 108 fresh P. falciparum isolates from southern Laos. The geometric mean (95% confidence interval) 50% inhibitory concentration values (nmol/L) were 152.4 (123.8-187.6) for chloroquine, 679.8 (533.8-863.0) for quinine, 45.9 (37.9-55.7) for mefloquine, 5.0 (4.4-6.4) for artesunate, 6.3 (4.5-8.9) for dihydroartemisinin, and 59.1 (46.4-75.3) for lumefantrine. The proportion of isolates defined as resistant were 65%, 40%, and 8% for chloroquine, quinine, and mefloquine, respectively. Of 53 isolates genotyped for the pfcrt T76K chloroquine-resistance mutation, 48 (91%) were mutants. P. falciparum in Laos is multi-drug resistant; antimalarial immunity resulting from the use of ineffective chloroquine before 2005 probably contributes significantly to the therapeutic responses in clinical trials. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.